Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Other Non Operating Income (2021 - 2025)

Prime Medicine (PRME) has disclosed Other Non Operating Income for 5 consecutive years, with $49000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 13.95% year-over-year to $49000.0, compared with a TTM value of $148000.0 through Dec 2025, up 260.98%, and an annual FY2025 reading of $148000.0, up 260.98% over the prior year.
  • Other Non Operating Income was $49000.0 for Q4 2025 at Prime Medicine, up from $44000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.1 million in Q1 2023 and bottomed at -$1.9 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is $139117.6, with a median of $42000.0 recorded in 2024.
  • The sharpest move saw Other Non Operating Income skyrocketed 72900.0% in 2022, then plummeted 310.04% in 2023.
  • Year by year, Other Non Operating Income stood at -$1000.0 in 2021, then surged by 92700.0% to $926000.0 in 2022, then tumbled by 310.04% to -$1.9 million in 2023, then skyrocketed by 102.21% to $43000.0 in 2024, then rose by 13.95% to $49000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for PRME at $49000.0 in Q4 2025, $44000.0 in Q3 2025, and $18000.0 in Q2 2025.